title: Pediatric suppositories of sulpiride solid dispersion for treatment of Tourette syndrome: in vitro and in vivo investigations.
abstract: Pharmaceutical development was adopted in the current study to propose a pediatric rectal formulation of sulpiride as a substitute to the available oral or parenteral formulations in the management of Tourette syndrome (TS). The goal was to formulate a product that is easy to use, stable, and highly bioavailable and to achieve a rapid clinical efficacy. Towards this aim, sulpiride solid dispersion (SD) with tartaric acid at a weight ratio of 1:0.25 was incorporated into different suppository bases, namely witepsol W25, witepsol H15, witepsol E75, suppocire NA, suppocire A, glycerogelatin, and polyethylene glycols. The formulae were evaluated in vitro using different pharmacotechnical methods such as visual, melting, weight and content uniformities, drug release, differential scanning calorimetry (DSC), Fourier transform infrared (FTIR), and X-ray diffraction (XRD) analyses. In vivo bioavailability was also assessed in rabbits to compare the bioavailability of either raw sulpiride-incorporated or its SD-incorporated witepsol H15-based suppositories to its oral suspension (reference). Sulpiride SD-incorporated witepsol H15 formulation showed acceptable in vitro characteristics with a bioavailability of 117% relative to oral dosing, which excel that in humans (27% after dosing of oral product). In addition, the proposed formula not only passed the 6-month stability study but also proposed a promising scale-up approach. Hence, it showed a great potential for pediatric product development to manage TS in rural areas.
authors.affiliation: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt, aszidan@kau.edu.sa.
authors.forename: Ahmed S
authors.initials: AS
authors.lastname: Zidan
authors.forename: Sherif E
authors.initials: SE
authors.lastname: Emam
authors.forename: Tamer M
authors.initials: TM
authors.lastname: Shehata
authors.forename: Fakhr-eldin S
authors.initials: FE
authors.lastname: Ghazy
mesh_terms: D000818:Animals; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning / Q000379:methods; D002626:Chemistry, Pharmaceutical / Q000379:methods; D008297:Male; D011092:Polyethylene Glycols / Q000737:chemistry; D011817:Rabbits; D013469:Sulpiride / Q000737:chemistry* / Q000494:pharmacology*; D013488:Suppositories / Q000737:chemistry* / Q000494:pharmacology*; D005879:Tourette Syndrome / Q000188:drug therapy*; D014280:Triglycerides / Q000737:chemistry; D014961:X-Ray Diffraction / Q000379:methods
chemical_list: D013488:Suppositories; D014280:Triglycerides; C009683:witepsol; D011092:Polyethylene Glycols; D013469:Sulpiride